Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease

Trial Profile

Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 11 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Feb 2012 Company added as trial sponsor (Eisai Inc) as reported by ClinicalTrials.gov.
    • 06 Feb 2012 Additional lead trial investigator (Shoya Yamakawa) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top